Nanoparticle mediated silencing of DNA repair sensitizes pediatric brain tumor cells to γ-irradiation

Molecular Oncology

Volumn 9, Issue 6, 2015, Pages 1071-1080

  Kievit, Forrest M ^a   Stephen, Zachary R ^b   Wang, Kui ^b   Dayringer, Christopher J ^b   Sham, Jonathan G ^a   Ellenbogen, Richard G ^a   Silber, John R ^a   Zhang, Miqin ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b University of Washington   (United States)

Author keywords

Ape1; Base excision repair; Ependymoma; Medulloblastoma; Nanomedicine; SiRNA

Indexed keywords

APURINIC ENDONUCLEASE 1; CHITOSAN; ENDONUCLEASE; MACROGOL; NANOPARTICLE; PACLITAXEL; POLYETHYLENEIMINE; SMALL INTERFERING RNA; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; UNCLASSIFIED DRUG; APEX1 PROTEIN, HUMAN; DNA (APURINIC OR APYRIMIDINIC SITE) LYASE; RADIOSENSITIZING AGENT; TUMOR PROTEIN;

ARTICLE; BIOCOMPATIBILITY; BIODEGRADABILITY; CANCER SURVIVAL; CELL SURVIVAL; CHILDHOOD CANCER; CLONOGENIC ASSAY; CONTROLLED STUDY; DNA REPAIR; EPENDYMOMA; EXCISION REPAIR; GAMMA IRRADIATION; HUMAN; HUMAN CELL; MEDULLOBLASTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; RADIOSENSITIZATION; TARGET CELL; BIOSYNTHESIS; BRAIN NEOPLASMS; DRUG EFFECTS; GAMMA RADIATION; METABOLISM; PATHOLOGY; RADIATION RESPONSE; TUMOR CELL LINE;

BRAIN NEOPLASMS; CELL LINE, TUMOR; DNA REPAIR; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; EPENDYMOMA; GAMMA RAYS; HUMANS; MEDULLOBLASTOMA; NANOPARTICLES; NEOPLASM PROTEINS; RADIATION-SENSITIZING AGENTS;

EID: 84929517261     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2015.01.006     Document Type: Article

References (49)

1. Abbotts R., Jewell R., Nsengimana J., Maloney D.J., Simeonov A., Seedhouse C., Elliott F., Laye J., Walker C., Jadhav A., Grabowska A., Ball G., Patel P.M., Newton-Bishop J., Wilson D.M., Madhusudan S. Targeting human apurinic/apyrimidinic endonuclease 1 (APE1) in phosphatase and tensin homolog (PTEN) deficient melanoma cells for personalized therapy. Oncotarget 2014, 5:3273-3286.
2. Abbotts R., Madhusudan S. Human AP endonuclease 1 (APE1): from mechanistic insights to druggable target in cancer. Cancer Treat. Rev. 2010, 36:425-435.
3. Al-Safi R.I., Odde S., Shabaik Y., Neamati N. Small-molecule inhibitors of APE1 DNA repair function: an overview. Curr. Mol. Pharmacol. 2012, 5:14-35.
4. Bobola M.S., Blank A., Berger M.S., Stevens B.A., Silber J.R. Apurinic/apyrimidinic endonuclease activity is elevated in human adult gliomas. Clin. Cancer Res. 2001, 7:3510-3518.
5. Bobola M.S., Finn L.S., Ellenbogen R.G., Geyer J.R., Berger M.S., Braga J.M., Meade E.H., Gross M.E., Silber J.R. Apurinic/apyrimidinic endonuclease activity is associated with response to radiation and chemotherapy in medulloblastoma and primitive neuroectodermal tumors. Clin. Cancer Res. 2005, 11:7405-7414.
6. Bobola M.S., Jankowski P.P., Gross M.E., Schwartz J., Finn L.S., Blank A., Ellenbogen R.G., Silber J.R. Apurinic/apyrimidinic endonuclease is inversely associated with response to radiotherapy in pediatric ependymoma. Int. J. Cancer 2011, 129:2370-2379.
7. Chithrani B.D., Chan W.C. Elucidating the mechanism of cellular uptake and removal of protein-coated gold nanoparticles of different sizes and shapes. Nano Lett. 2007, 7:1542-1550.
8. Chithrani B.D., Ghazani A.A., Chan W.C. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett. 2006, 6:662-668.
9. Davis M.E., Zuckerman J.E., Choi C.H., Seligson D., Tolcher A., Alabi C.A., Yen Y., Heidel J.D., Ribas A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464:1067-1070.
10. Demple B., Harrison L. Repair of oxidative damage to DNA: enzymology and biology. Annu. Rev. Biochem. 1994, 63:915-948.
11. Dolecek T.A., Propp J.M., Stroup N.E., Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro-oncology 2012, 14(Suppl. 5):v1-v49.
12. Dorjsuren D., Kim D., Vyjayanti V.N., Maloney D.J., Jadhav A., Wilson D.M., Simeonov A. Diverse small molecule inhibitors of human apurinic/apyrimidinic endonuclease APE1 identified from a screen of a large public collection. PLoS One 2012, 7:e47974.
13. Fang C., Kievit F.M., Veiseh O., Stephen Z.R., Wang T.Z., Lee D.H., Ellenbogen R.G., Zhang M.Q. Fabrication of magnetic nanoparticles with controllable drug loading and release through a simple assembly approach. J.Control. Release 2012, 162:233-241.
14. Fung H., Demple B. Distinct roles of Ape1 protein in the repair of DNA damage induced by ionizing radiation or bleomycin. J.Biol. Chem. 2011, 286:4968-4977.
15. Georgakilas A.G., Bennett P.V., Wilson D.M., Sutherland B.M. Processing of bistranded abasic DNA clusters in gamma-irradiated human hematopoietic cells. Nucleic Acids Res. 2004, 32:5609-5620.
16. Huse J.T., Holland E.C. Genetically engineered mouse models of brain cancer and the promise of preclinical testing. Brain Pathol. 2009, 19:132-143.
17. Kelley M.R., Georgiadis M.M., Fishel M.L. APE1/Ref-1 role in redox signaling: translational applications of targeting the redox function of the DNA repair/redox protein APE1/Ref-1. Curr. Mol. Pharmacol. 2012, 5:36-53.
18. Kievit F.M., Veiseh O., Bhattarai N., Fang C., Gunn J.W., Lee D., Ellenbogen R.G., Olson J.M., Zhang M. PEI-PEG-chitosan copolymer coated iron oxide nanoparticles for safe gene delivery: synthesis, complexation, and transfection. Adv. Funct. Mater. 2009, 19:2244-2251.
19. Kievit F.M., Veiseh O., Fang C., Bhattarai N., Lee D., Ellenbogen R.G., Zhang M. Chlorotoxin labeled magnetic nanovectors for targeted gene delivery to glioma. ACS Nano 2010, 4:4587-4594.
20. Kievit F.M., Zhang M. Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers. Adv. Mater. 2011, 23:H217-H247.
21. Kievit F.M., Zhang M. Surface engineering of iron oxide nanoparticles for targeted cancer therapy. Acc. Chem. Res. 2011, 44:853-862.
22. Kilday J.P., Rahman R., Dyer S., Ridley L., Lowe J., Coyle B., Grundy R. Pediatric ependymoma: biological perspectives. Mol. Cancer Res. - MCR 2009, 7:765-786.
23. Kubo K., Ide H., Wallace S.S., Kow Y.W. A novel, sensitive, and specific assay for abasic sites, the most commonly produced DNA lesion. Biochemistry 1992, 31:3703-3708.
24. Lannering B., Rutkowski S., Doz F., Pizer B., Gustafsson G., Navajas A., Massimino M., Reddingius R., Benesch M., Carrie C., Taylor R., Gandola L., Bjork-Eriksson T., Giralt J., Oldenburger F., Pietsch T., Figarella-Branger D., Robson K., Forni M., Clifford S.C., Warmuth-Metz M., von Hoff K., Faldum A., Mosseri V., Kortmann R. Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial. J.Clin. Oncol. - Off. J. Am. Soc. Clin. Oncol. 2012, 30:3187-3193.
25. Liu L., Gerson S.L. Therapeutic impact of methoxyamine: blocking repair of abasic sites in the base excision repair pathway. Curr. Opin. Investig. Drugs 2004, 5:623-627.
26. Lord C.J., Ashworth A. The DNA damage response and cancer therapy. Nature 2012, 481:287-294.
27. Lyons S.A., O'Neal J., Sontheimer H. Chlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin. Glia 2002, 39:162-173.
28. Mok H., Veiseh O., Fang C., Kievit F.M., Wang F.Y., Park J.O., Zhang M. pH-Sensitive siRNA nanovector for targeted gene silencing and cytotoxic effect in cancer cells. Mol. Pharm. 2010, 7:1930-1939.
29. Mueller S., Chang S. Pediatric brain tumors: current treatment strategies and future therapeutic approaches. Neurotherapeutics - J. Am. Soc. Exp. NeuroTherapeutics 2009, 6:570-586.
30. Northcott P.A., Jones D.T., Kool M., Robinson G.W., Gilbertson R.J., Cho Y.J., Pomeroy S.L., Korshunov A., Lichter P., Taylor M.D., Pfister S.M. Medulloblastomics: the end of the beginning. Nat. Rev. Cancer 2012, 12:818-834.
31. Pecot C.V., Calin G.A., Coleman R.L., Lopez-Berestein G., Sood A.K. RNA interference in the clinic: challenges and future directions. Nat. Rev. Cancer 2011, 11:59-67.
32. Robertson A.B., Klungland A., Rognes T., Leiros I. DNA repair in mammalian cells: base excision repair: the long and short of it. Cell Mol. Life Sci. - CMLS 2009, 66:981-993.
33. Silber J.R., Bobola M.S., Blank A., Schoeler K.D., Haroldson P.D., Huynh M.B., Kolstoe D.D. The apurinic/apyrimidinic endonuclease activity of Ape1/Ref-1 contributes to human glioma cell resistance to alkylating agents and is elevated by oxidative stress. Clin. Cancer Res. 2002, 8:3008-3018.
34. Soroceanu L., Gillespie Y., Khazaeli M.B., Sontheimer H. Use of chlorotoxin for targeting of primary brain tumors. Cancer Res. 1998, 58:4871-4879.
35. Srinivasan A., Wang L., Cline C.J., Xie Z., Sobol R.W., Xie X.Q., Gold B. Identification and characterization of human apurinic/apyrimidinic endonuclease-1 inhibitors. Biochemistry 2012, 51:6246-6259.
36. Stuben G., Stuschke M., Kroll M., Havers W., Sack H. Postoperative radiotherapy of spinal and intracranial ependymomas: analysis of prognostic factors. Radiother. Oncol. - J. Eur. Soc. Ther. Radiol. Oncol. 1997, 45:3-10.
37. Sultana R., McNeill D.R., Abbotts R., Mohammed M.Z., Zdzienicka M.Z., Qutob H., Seedhouse C., Laughton C.A., Fischer P.M., Patel P.M., Wilson D.M., Madhusudan S. Synthetic lethal targeting of DNA double-strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors. Int. J. Cancer 2012, 131:2433-2444.
38. Sutherland B.M., Bennett P.V., Sidorkina O., Laval J. Clustered DNA damages induced in isolated DNA and in human cells by low doses of ionizing radiation. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:103-108.
39. Tamburrini G., D'Ercole M., Pettorini B.L., Caldarelli M., Massimi L., Di Rocco C. Survival following treatment for intracranial ependymoma: a review. Childs Nerv. Syst. - ChNS - Off. J. Int. Soc. Pediatr. Neurosurg. 2009, 25:1303-1312.
40. Veiseh M., Gabikian P., Bahrami S.B., Veiseh O., Zhang M., Hackman R.C., Ravanpay A.C., Stroud M.R., Kusuma Y., Hansen S.J., Kwok D., Munoz N.M., Sze R.W., Grady W.M., Greenberg N.M., Ellenbogen R.G., Olson J.M. Tumor paint: a chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci. Cancer Res. 2007, 67:6882-6888.
41. Veiseh O., Kievit F.M., Fang C., Mu N., Jana S., Leung M.C., Mok H., Ellenbogen R.G., Park J.O., Zhang M. Chlorotoxin bound magnetic nanovector tailored for cancer cell targeting, imaging, and siRNA delivery. Biomaterials 2010, 31:8032-8042.
42. Veiseh O., Sun C., Fang C., Bhattarai N., Gunn J., Kievit F., Du K., Pullar B., Lee D., Ellenbogen R.G., Olson J., Zhang M. Specific targeting of brain tumors with an optical/magnetic resonance imaging nanoprobe across the blood-brain barrier. Cancer Res. 2009, 69:6200-6207.
43. Wang T., Kievit F.M., Veiseh O., Arami H., Stephen Z.R., Fang C., Liu Y., Ellenbogen R.G., Zhang M. Targeted cell uptake of a noninternalizing antibody through conjugation to iron oxide nanoparticles in primary central nervous system lymphoma. World Neurosurg. 2013, 80:134-141.
44. Whitehead K.A., Dorkin J.R., Vegas A.J., Chang P.H., Veiseh O., Matthews J., Fenton O.S., Zhang Y., Olejnik K.T., Yesilyurt V., Chen D., Barros S., Klebanov B., Novobrantseva T., Langer R., Anderson D.G. Degradable lipid nanoparticles with predictable invivo siRNA delivery activity. Nat. Commun. 2014, 5:4277.
45. Whitehead K.A., Langer R., Anderson D.G. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 2009, 8:129-138.
46. Wilson D.M., Simeonov A. Small molecule inhibitors of DNA repair nuclease activities of APE1. Cell Mol. Life Sci. CMLS 2010, 67:3621-3631.
47. Witt H., Korshunov A., Pfister S.M., Milde T. Molecular approaches to ependymoma: the next step(s). Curr. Opin. Neurol. 2012, 25:745-750.
48. Yang N., Chaudhry M.A., Wallace S.S. Base excision repair by hNTH1 and hOGG1: a two edged sword in the processing of DNA damage in gamma-irradiated human cells. DNA Repair 2006, 5:43-51.
49. Zhang S., Li J., Lykotrafitis G., Bao G., Suresh S. Size-dependent endocytosis of nanoparticles. Adv. Mater. 2009, 21:419-424.